



DEPARTMENT OF HEALTH & HUMAN SERVICES

M 880 N

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

MAR 5 1997

WARNING LETTER

VIA FEDERAL EXPRESS

Mr. Bruno Toniolo
President
Internazionale Medico Scientifica, s.r.l.
Via Sagittario, 5
40044 Pontecchio Marconi
Sasso Marconi, Bologna
ITALY

Dear Mr. Toniolo:

During an inspection of your firm located in Bologna, Italy, on December 16-20, 1996, the Food and Drug Administration (FDA) investigator determined that your firm manufactures mammography systems, Model GIOTTO. This product is a device as defined by section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act). Additionally, this device is subject to section 538 of Subchapter C - Electronic Product Radiation of Chapter V of the Act.

The above-stated inspection revealed that these devices are adulterated under section 501(h) of the Act, in that the methods used in, and the facilities or controls used for the manufacturing, packing, storage, and installation are not in conformance with the Good Manufacturing Practice (GMP) for Medical Devices Regulations, as specified in Title 21, Code of Federal Regulations (21 CFR), Part 820 as follows:

1. Failure to establish and implement specification control measures to assure that the design basis for the devices is correctly translated into approved specifications, as required by 21 CFR 820.100(a)(1). For example, the validation documentation was not available for the operation of the Giotto and units; including verification of the software functions with the mammography device.

Your response may be adequate if verified by documentation showing implementation. Your response noted that this deficiency would be completed by mid-February.

Page 2 - Mr. Toniolo

2. Failure to have adequate written procedures for testing components for conformance to specifications as required by 21 CFR 820.80(a). For example, the incoming inspection procedure () for components does not include testing procedures (or corresponding testing records) for EPROMS and circuit boards (w/EPROMS) used in the Giotto () and () devices (e.g.: (), () and () incoming components and EPROMS).

Your response may be adequate if verified by documentation showing implementation. Your response noted that a new procedure would be applied in March.

3a. Failure to establish and implement specification control measures to assure that the design basis for the devices is correctly translated into approved specifications, as required by 21 CFR 820.100(a)(1). For example, there are no records for the programming of EPROMS.

3b. Failure to maintain a record of component acceptance or rejection, as required by 21 CFR 820.80(a). For example, there are no records for the success/failure of the EPROM programming operation.

3c. Failure of the Device Master Record to include device production environment specifications as required by 21 CFR 820.181. For example, there are no written procedure referencing any electro-static discharge (ESD) controls used during production.

3d. Failure to have written procedures for acceptance of components, as required by 21 CFR 820.80(a). For example, there is no procedure for the storage of memory components.

Your response may be adequate for items 3a-3d if verified by documentation showing implementation.

4. Failure of the device master record to be signed and dated by a designated individual(s), as required by 21 CFR 820.181. For example, the master and working copies of software for EPROMS used in Giotto () and () devices were not observed signed/dated as approved.

Your response may be adequate if verified by documentation showing implementation.

5. Failure of the quality assurance program to assure the review of production records, as required by 21 CFR 820.20(a)(1). For example, there is inadequate review, or no procedure for review, of records by QA/QC for:

- a) the review, evaluation, and closure of complaints by QA.
- b) the final quality test on Giotto units.
- c) the production checks or components for the Giotto device.
- d) "Project" and "Minor" change control documents.

Your response is not adequate. Although your response noted that you had modified several procedures and forms relative to the above-mentioned deficiencies, e.g. "Customers' Complaints Handling" and form "Customer Complaint" which QA will verify that complaints have been reviewed, evaluated and closed-out, none of these documents were provided with your response so that we could determine the adequacy of your corrections.

6. Failure of the device master record to be signed and dated by a designated individual(s), as required by 21 CFR 820.181. For example, the Device Master Records for the Giotto didn't contain:

- a) the approval signature/date and revision No. of the Operator's Instruction Manual.

Your response may be adequate for item 6(a) if verified by documentation showing implementation.

- b) the approval signature/date of all original labeling applied to Giotto devices.
- c) the approval of the "List of Components" for Giotto series and

Your response is not adequate for items 6(b) and 6(c). Your response noted that QA had signed and approved the original labels for the Giotto devices. Also, the list of components for the Giotto series and had been approved by QA. However, you did not provide any documentation to confirm these corrections.

Page 4 - Mr. Toniolo

7. Failure to document training programs, where training programs are necessary to assure that personnel have a thorough understanding of their jobs, as required by 21 CFR 820.25(a). For example, the training record documentation was not complete and approved for individuals who perform: QA/QC functions, technical/finished product testing, incoming inspection, and complaint handling.

Your response may be adequate, if verified by documentation.

We acknowledge that you have submitted a response dated January 23, 1997, concerning our investigator's observations noted on the form FDA 483. We have reviewed your response and have concluded that it is inadequate for the reasons cited above.

This letter is not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure adherence to each requirement of the Act and regulations. The specific violations noted in this letter and in the FDA 483 issued at the close of the inspection may be symptomatic of serious underlying problems in your firm's manufacturing and quality assurance systems. You are responsible for investigating and determining the causes of the violations identified by the FDA. If the causes are determined to be systems problems, you must promptly initiate permanent corrective actions.

Federal agencies are advised of the issuance of all Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, no premarket submissions for devices to which the GMP deficiencies are reasonably related will be cleared until the violations have been corrected.

Your devices are already on detention based on a previous establishment inspection of October 2-6, 1995. Given the serious nature of these violations of the Act, all devices manufactured by Internazionale Medico Scientifica, Bologna, Italy, may continue to be refused entry into the U.S. until these violations are corrected. You should take prompt action to correct these deviations.

In order to remove the devices from this detention, it will be necessary for you to provide a written response to the charges in this Warning Letter for our review. After your response is received for the seven GMP deficiencies listed

Page 5 - Mr. Toniolo

above and reviewed by this office, you will be notified of its adequacy. It will be your responsibility to schedule another FDA inspection of your facility. As soon as the inspection has taken place, the implementation of your corrections have been verified, and you are notified that your corrections are adequate, your products may resume entry into this country.

Please notify this office within 15 working days of receipt of this letter of the specific steps you have taken, or intend to take, to correct the noted violations, including an explanation of each step being taken to prevent the recurrence of similar violations. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Please include any and all documentation to show that adequate corrections have been achieved. In the case of future corrections, an estimated date of completion, and documentation showing plans for correction, should be included with your response to this letter. If the documentation is not in English, please provide a translation to facilitate our review. Please address your response to:

)

Thomas M. Jakub, Chief
Diagnostic Devices Branch, HFZ-322
Food and Drug Administration
Center for Devices and Radiological Health
Office of Compliance
Division of Enforcement I
2098 Gaither Road
Rockville, Maryland 20850 USA

Should you require any assistance in understanding the contents of this letter, do not hesitate to contact Ms. Fleadia R. Farrah at the above address or at (301) 594-4591 or FAX (301) 594-4636.

Sincerely yours,

LJG

Lillian J. Gill
Director
Office of Compliance
Center for Devices and
Radiological Health